Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average PT from Brokerages
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The […]
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The […]
